Etoshine NP Tablet PR
Product introduction
Etoshine NP Tablet PR can be taken with or without food, but it is important to take this medicine at the same time each day to get the most benefit. The exact dose and duration of treatment will depend on your condition and how you respond to it. Your doctor will probably start this medicine at a low dose and increase it gradually. It may take a few weeks for the medicine to work properly. Follow your doctor’s instructions and continue taking it regularly until your doctor advises you to stop. Do not miss any dose, otherwise, your condition may worsen.
The side effects of this medicine are usually mild and go away by themselves. The most common ones are feeling sleepy or dizzy, dryness in the mouth, blurred vision, weight gain, edema (swelling over the whole body), and difficulty in concentrating. Most side effects are not serious and do not need medical attention. Talk to your doctor about potential side effects and ways in which you might prevent or cope with them.
Before taking the medicine you should tell your doctor if you are pregnant, breastfeeding or planning to become pregnant. Be careful while driving as sleepiness, dizziness, and blurring of vision may be seen as side effects. You should avoid drinking alcohol along with this medicine as it may lead to excessive sleepiness and dizziness.
Uses of Etoshine NP Tablet PR
Benefits of Etoshine NP Tablet PR
In Neuropathic pain
Side effects of Etoshine NP Tablet PR
Common side effects of Etoshine NP
- Dizziness
- Sleepiness
- Dryness in mouth
- Swelling
- Blurred vision
- Weight gain
- Impaired concentration
- Stomach pain
- Headache
- Fatigue
- Increased appetite
How to use Etoshine NP Tablet PR
How Etoshine NP Tablet PR works
Safety advice
All substitutes
Quick tips
- Etoshine NP Tablet PR should be taken as per the dose and duration prescribed by your doctor.
- Do not skip any dose and finish the complete course even if you feel better.
- It may cause sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- It may cause blurring or loss of vision. Inform your doctor immediately if you notice any vision changes.
- During long-term treatment, your doctor may want to take regular blood tests to monitor your liver function.
- Etoshine NP Tablet PR should be taken as per the dose and duration prescribed by your doctor.
- Do not skip any dose and finish the complete course even if you feel better.
- It may cause sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- It may cause blurring or loss of vision. Inform your doctor immediately if you notice any vision changes.
- During long-term treatment, your doctor may want to take regular blood tests to monitor your liver function.
Fact Box
Patient concerns
User feedback
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Stahl SM, editor. Pregabalin. In: Stahl's Essential Pschopharmacology: Prescriber's Guide. 5th ed. New York, New York: Cambridge University Press; 2014. pp. 557-60.
- McNamara JO. Pharmacotherapy of the Epilepsies. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 599.
- Grosser T, Smyth E, FitzGerald GA. Anti-Inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 992.